Mycophenolate Mofetil

Kidney Transplantation

Volumn , Issue , 2008, Pages 277-292

  Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954564379     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3343-1.50022-0     Document Type: Chapter

References (166)

1. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002, 74:1725.
2. Afzali B, Shah S, Chowdhury P, et al. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005, 79:304.
3. Allison AC, Eugui EM Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993, 136:5.
4. Allison AC, Hovi T, Watts RW, et al. Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de-novo purine synthesis in lymphocyte transformation. Lancet 1975, 2:1179.
5. Allison AC, Kowalski WJ, Muller CJ, et al. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block glycosylation of adhesion molecules. Transplant Proc 1993, 25:67.
6. Apostolou T, Tsagalis G, Koutroubas G, et al. Mycophenolate mofetil and oral ulcerations. Transplantation 2004, 77:1911.
7. Arns W Noninfectious gastrointestinal complications of mycophenolic acid therapy: a consequence of local GI toxicity. Transplant Proc 2007, 39:88.
8. Atcheson BA, Taylor PJ, Mudge DW, et al. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol 2005, 59:271.
9. Augustine JJ, Chang PC, Knauss TC, et al. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. Transplantation 2006, 81:1004.
10. Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004, 4:2001.
11. Azuma H, Binder J, Heemann U, et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995, 59:460.
12. Badid C, Vincent M, McGregor B, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000, 58:51.
13. Banerjee R, Halil O, Bain BJ, et al. Neutrophil dysplasia caused by mycophenolate mofetil. Transplantation 2000, 70:1608.
14. Bedrossian CW, Sussman J, Conklin RH, et al. Azathioprine-associated interstitial pneumonitis. Am J Clin Pathol 1984, 82:148.
15. Bennett WM Immunosuppression with mycophenolic acid: one size does not fit all. J Am Soc Nephrol 2003, 14:2414.
16. Birkeland SA Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation 1998, 66:1207.
17. Blaheta RA, Bogossian H, Beecken WD, et al. Mycophenolate mofetil increases adhesion capacity of tumor cells in vitro. Transplantation 2003, 76:1735.
18. Blaheta RA, Nelson K, Oppermann E, et al. Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogeneic T cells or cytokines. Transplantation 2000, 69:1977.
19. Budde K, Braun KP, Glander P, et al. Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients. Transplant Proc 2002, 34:1748.
20. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004, 4:237.
21. Bullingham R, Monroe S, Nicholls A, et al. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after singledose oral and intravenous administration. J Clin Pharmacol 1996, 36:315.
22. Bunnapradist S, Daswani A, Takemoto SK Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. Transplantation 2003, 76:10.
23. Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993, 268:27286.
24. Cattaneo D, Gaspari F, Ferrari S, et al. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 2001, 15:402.
25. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002, 62:1060.
26. Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006, 81:1290.
27. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation, I: drug interactions and rejection at one year. Transplantation 2004, 77:244.
28. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immunemonitoring. Transplantation 2005, 80:457.
29. Ciancio G, Burke GW, Suzart K, et al. The use of daclizumab, tacrolimus and mycophenolate mofetil in African-American and Hispanic first renal transplant recipients. Am J Transplant 2003, 3:1010.
30. Cohn RG, Mirkovich A, Dunlap B, et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999, 68:411.
31. Colic M, Stojic-Vukanic Z, Pavlovic B, et al. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 2003, 134:63.
32. Deierhoi MH, Kauffman RS, Hudson SL, et al. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg 1993, 217:476.
33. Downs SM Induction of meiotic maturation in vivo in the mouse by IMP dehydrogenase inhibitors: effects on the developmental capacity of ova. Mol Reprod Dev 1994, 38:293.
34. Ducloux D, Ottignon Y, Semhoun-Ducloux S, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation 1998, 66:1115.
35. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005, 79:466.
36. Elli A, Aroldi A, Montagnino G, et al. Mycophenolate mofetil and cough. Transplantation 1998, 66:409.
37. Eugui EM, Almquist SJ, Muller CD, et al. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991, 33:161.
38. Figueroa J, Fuad SA, Kunjummen BD, et al. Suppression of synthesis of natural antibodies by mycophenolate mofetil (RS-61443): its potential use in discordant xenografting. Transplantation 1993, 55:1371.
39. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002, 74:1070.
40. Franklin TJ, Cook JM The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969, 113:515.
41. Fu YF, Liu GL Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclosphosphamide and cyclosporine. Clin Nephrol 2001, 55:318.
42. Fulton B, Markham A Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996, 51:278.
43. Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006, 6:1617.
44. Garrigue V, Canet S, Dereure O, et al. Oral ulcerations in a renal transplant recipient: a mycophenolate mofetil-induced complication?. Transplantation 2001, 72:968.
45. Giblett ER, Anderson JE, Cohen F, et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972, 2:1067.
46. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004, 4:2045.
47. Glicklich D, Gupta B, Schurter-Frey G, et al. Chronic renal allograft rejection: no response to mycophenolate mofetil. Transplantation 1998, 66:398.
48. Gosio B Sperimentate su culture pure di bacilli del carbonchio demonstrarano notevole potere antisettica. C R Acad Med Torino 1893, 61:484.
49. Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003, 75:1213.
50. Gonzalez Molina M, Seron D, Garcia del Moral R, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy: a follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004, 77:215.
51. Grailer A, Nichols J, Hullett D, et al. Inhibition of human B cell responses in vitro by RS-61443, cyclosporine A and DAB486 IL-2. Transplant Proc 1991, 23:314.
52. Gregoor PJ, de Sevaux RG, Hene RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999, 68:1603.
53. Grinyo JM, Gil-Vernet S, Cruzado JM, et al. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 2003, 16:820.
54. Guerard A, Rabodonirina M, Cotte L, et al. Intestinal microsporidiosis occurring in two renal transplant recipients treated with mycophenolate mofetil. Transplantation 1999, 68:699.
55. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998, 64:672.
56. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997, 63:39.
57. Hauser IA, Renders L, Radeke HH, et al. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999, 14:58.
58. Holt DW Monitoring mycophenolic acid. Ann Clin Biochem 2002, 39:173.
59. Hubner GI, Eismann R, Sziegoleit W Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients. Arzneimittelforschung 2000, 50:936.
60. Hueso M, Bover J, Seron D, et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998, 66:1727.
61. Ishida H, Tanabe K, Furusawa M, et al. Mycophenolate mofetil suppresses the production of anti-blood type antibodies after renal transplantation across the ABO blood barrier: ELISA to detect humoral activity. Transplantation 2002, 74:1187.
62. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000, 69:834.
63. Johnson DW, Nicol DL, Purdie DM, et al. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients?. Transplantation 2002, 73:1158.
64. Jolicoeur EM, Qi S, Xu D, et al. Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. Transplantation 2003, 75:54.
65. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003, 35:25S.
66. Karim MY, Alba P, Cuadrado MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxf) 2002, 41:876.
67. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80:883.
68. Keown PA, Sullivan SD, Best JH, et al: Economic evaluation of mycophenolate mofetil for prevention of acute graft rejection after cadaveric renal transplantation in Canada. Presented at the American Society of Transplant Physicians 16th annual meeting, Chicago, III, May 1997.
69. Khwaja K, Asolati M, Harmon J, et al. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant 2004, 4:980.
70. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004, 4:1079.
71. Kimball JA, Pescovitz MD, Book BK, et al. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995, 60:1379.
72. Klupp J, Dambrin C, Hibi K, et al. Treatment by mycophenolate mofetil of advanced graft vascular disease in non-human primate recipients of orthotopic aortic allografts. Am J Transplant 2003, 3:817.
73. Kobayashi M, Saitoh H, Kobayashi M, et al. Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats. J Pharmacol Exp Ther 2004, 309:1029.
74. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000, 69:1252.
75. Kuypers DR, Claes K, Evenepoel P, et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004, 75:434.
76. Kuypers DR, Evenepoel P, Maes B, et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003, 17:234.
77. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003, 25:609.
78. Land W, Schneeberger H, Weiss M, et al. Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. Transplant Proc 2001, 33:29S.
79. Land W, Vincenti F Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation 2005, 80:S221.
80. Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003, 75:37.
81. Lee WA, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990, 7:161.
82. Louis-Touizer C, Nuijten MJ, Bayle F, et al. [Economic contribution of mofetil mycofenolate as preventive immunosuppressive treatment after renal transplantation from cadaver]. Presse Med 1996, 25:1577.
83. Lowe JK, Brox L, Henderson JF Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole. Cancer Res 1977, 37:736.
84. Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003, 75:665.
85. Maes BD, van Pelt JF, Peeters JC, et al. The effect of mycophenolate mofetil on hepatitis B viral load in stable renal transplant recipients with chronic hepatitis B. Transplantation 2001, 72:1165.
86. McMurray RW, Elbourne KB, Lagoo A, et al. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus. J Rheumatol 1998, 25:2364.
87. Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003, 3:68.
88. Meier-Kriesche HU, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003, 75:1341.
89. Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005, 80:303.
90. Merville P, Berge F, Deminiere C, et al. Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant 2004, 4:1769.
91. Millan O, Oppenheimer F, Brunet M, et al. Assessment of mycophenolic acid-induced immunosuppression: a new approach. Clin Chem 2000, 46:1376.
92. Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000, 69:875.
93. Moon JI, Kim YS, Kim MS, et al. Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study. Transplant Proc 2000, 32:2026.
94. Morris RG Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?. Ann Pharmacother 2005, 39:119.
95. Morris RE, Wang J, Blum JR, et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 1991, 23:19.
96. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation 1998, 65:235.
97. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation 2001, 71:1091.
98. Mycophenolate mofetil in renal transplantation 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation 1999, 68:391.
99. Neylan JF, for the U, S, Renal Transplant Mycophenolate Mofetil Study Group Immunosuppressive therapy in high-risk transplant patients: dose dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997, 64:1277.
100. Neyts J, Andrei G, De Clercq E The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998, 42:216.
101. Nowak I, Shaw LM Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995, 41:1011.
102. Ogawa N, Nagashima N, Nakamura M, et al. Measurement of mycophenolate mofetil effect in transplant recipients. Transplantation 2001, 72:422.
103. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000, 69:2405.
104. Oz HS, Hughes WT Novel anti- Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997, 175:901.
105. Papadimitriou JC, Drachenberg CB, Beskow CO, et al. Graft-versushost disease-like features in mycophenolate mofetil-related colitis. Transplant Proc 2001, 33:2237.
106. Pape L, Froede K, Strehlau J, et al. Alterations of cyclosporin A metabolism induced by mycophenolate mofetil. Pediatr Transplant 2003, 7:302.
107. Pascual J, Quereda C, Zamora J, et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004, 78:1548.
108. Pascual M, Curtis J, Delmonico FL, et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003, 75:1501.
109. Pawinski T, Durlik M, Szlaska I, et al. The weight of pharmacokinetic parameters for mycophenolic acid in prediction of rejection outcome: the receiver operating characteristic curve analysis. Transplant Proc 2006, 38:86.
110. Pergola PE, Kancharla A, Riley DJ Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation 2001, 71:994.
111. Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant 2003, 3:1581.
112. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995, 345:1321.
113. Qiu Y, Fairbanks LD, Ruckermann K, et al. Mycophenolic acid- induced GTP depletion also affects ATP and pyrimidine synthesis in mitogen-stimulated primary human T-lymphocytes. Transplantation 2000, 69:890.
114. Quemeneur L, Flacher M, Gerland LM, et al. Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis. J Immunol 2002, 169:2747.
115. Remuzzi G, Lesti M, Gotti E, et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004, 364:503.
116. Riskalla MM, Somers EC, Fatica RA, et al. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003, 30:1508.
117. Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005, 5:2954.
118. Rook M, Postma DS, van der Jagt EJ, et al. Mycophenolate mofetil and bronchiectasis in kidney transplant patients: a possible relationship. Transplantation 2006, 81:287.
119. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005, 79:807.
120. Rostaing L, Izopet J, Sandres K, et al. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000, 69:991.
121. Sadek S, Medina J, Arias M, et al. Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: a prospective, multicenter, randomized study. Transplantation 2002, 74:511.
122. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004, 4:231.
123. Schnitzler MA, Craig KE, Woodward RS, et al. Cost savings for lifetime immunosuppression from MMF in cadaveric renal transplant 2001, American Society of Transplantation, Chicago, Abstracts.
124. Schnitzler MA, Woodward RS, Lowell JA, et al. Ten year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation. Transplant Proc 1999, 31:19S.
125. Schnuelle P, van der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002, 13:536.
126. Schrama YC, Joles JA, van Tol A, et al. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 2000, 69:376.
127. Schweitzer EJ, Yoon S, Fink J, et al. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. Transplantation 1998, 65:242.
128. Senda M, DeLustro B, Eugui E, et al. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995, 60:1143.
129. Shaw LM, Korecka M, Aradhye S, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 2000, 40:624.
130. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003, 3:534.
131. Shihab FS, Bennett WM, Yi H, et al. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-betal. Transplantation 2004, 77:683.
132. Shihab FS, Bennett WM, Yi H, et al. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-betal in chronic cyclosporine nephrotoxicity. Am J Transplant 2003, 3:1550.
133. Shipkova M, Armstrong VW, Oellerich M, et al. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 2003, 25:1.
134. Shipkova M, Spielbauer B, Voland A, et al. cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy. Transplantation 2004, 78:1145.
135. Smak Gregoor PJ, van Gelder T, van Besouw NM, et al. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000, 70:143.
136. Sollinger HW Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995, 60:225.
137. Sollinger HW, Belzer FO, Deierhoi MH, et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992, 216:513.
138. Sollinger HW, Deierhoi MH, Belzer FO, et al. RS-61443-a phase I clinical trial and pilot rescue study. Transplantation 1992, 53:428.
139. Squifflet JP, Vanrenterghem Y, van Hooff JP, et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002, 34:1584.
140. Sureshkumar KK, Nghiem DD Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients. Transplantation 2003, 76:441.
141. Suwelack B, Gerhardt U, Hohage H Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004, 4:655.
142. Takahashi K, Ochiai T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee-Japan. Transplant Proc 1995, 27:1421.
143. ter Meulen CG, van Riemsdijk I, Hene RJ, et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. Am J Transplant 2004, 4:803.
144. The Mycophenolate Mofetil Renal Refractory Rejection Study Group Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996, 61:722.
145. Tran HT, Acharya MK, McKay DB, et al. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 2000, 11:1903.
146. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996, 61:1029.
147. Tuteja S, Alloway RR, Johnson JA, et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001, 71:1303.
148. Valentin JF, Bruijn JA, Paul LC Donor treatment with mycophenolate mofetil: protection against ischemia-reperfusion injury in the rat. Transplantation 2000, 69:344.
149. van Besouw NM, van der Mast BJ, Smak Gregoor PJ, et al. Effect of mycophenolate mofetil on erythropoiesis in stable renal transplant patients is correlated with mycophenolic acid trough levels. Nephrol Dial Transplant 1999, 14:2710.
150. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999, 68:261.
151. van Gelder T, Shaw LM The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005, 80:S244.
152. van Gelder T, ter Meulen CG, Hene R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003, 75:788.
153. Vanrenterghem Y, Lebranchu Y, Hene R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000, 70:1352.
154. Vincenti F, Monaco A, Grinyo J, et al. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. Transplant Proc 2001, 33:1011.
155. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003, 3:306.
156. Vincenti F, Muehlbacher F, Nashan B, et al; for LEA29Y Study Group: Co-stimulation blockade with LEA29Y in a calcineurin inhibitor-free maintenance regimen in renal transplant: 6-month efficacy and safety. American Transplant Congress, Boston, 2004 (abstract 1037).
157. Vu MD, Qi S, Xu D, et al. Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 1998, 66:1575.
158. Walpoth BH, Pavlicek M, Celik B, et al. Prevention of neointimal proliferation by immunosuppression in synthetic vascular grafts. Eur J Cardiothorac Surg 2001, 19:487.
159. Watanabe M, Yuzawa K, Homma M, et al. Establishment of animal model with side effects induced by mycophenolate mofetil and pharmaco-histological analysis of them. Transplant Proc 2006, 38:3323.
160. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 1999, 21:498.
161. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002, 13:759.
162. Wu JC Mycophenolate mofetil molecular mechanisms of action. Perspect Drug Discovery Design 1994, 2:185.
163. Young M, Plosker GL Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplantation. Pharmacoeconomics 2002, 20:675.
164. Zanker B, Schneeberger H, Rothenpieler U, et al. Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients. Transplantation 1998, 66:44.
165. Zeeh J, Inglin R, Baumann G, et al. Mycophenolate mofetil imparis helaing of left-sided colon anastomoses. Transplantation 2001, 71:1429.
166. Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999, 21:35.